Full text is available at the source.
Abstract
Evaluation of maternal, fetal, and neonatal outcomes following exposure to glucagon-like peptide-1 receptor agonists is essential.
- Maternal outcomes related to preconception or gestational exposure to these medications are being examined.
- Fetal impacts of glucagon-like peptide-1 receptor agonists and dual receptor agonists are under investigation.
- Neonatal outcomes are also a focus of this evaluation.
- The study aims to assess the consistency of previously reported safety signals associated with these treatments.
Simplified